Payment overview · 2025
General Payments
$1,041.38
8 reported records · 3 companies
Healthcare provider profile · identity verified
Mario E Guerrero Paneque, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MIAMI, FL · NPI 1285013847
Verified facts
What the public records show
CMS Open Payments records show Mario E Guerrero Paneque, ARNP received $1,041.38 in general payments during 2025 across 8 reported records.
Novartis Pharmaceuticals Corporation accounted for 91.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $950.68 | 91.3% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $71.89 | 6.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.81 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $591.30 | 2 |
| Food and Beverage | $450.08 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $950.68 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.89 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1156 | 336 |
| Gabapentin | Gabapentin | 777 | 238 |
| Metformin Hcl | Metformin Hcl | 749 | 221 |
| Omeprazole | Omeprazole | 681 | 195 |
| Losartan Potassium | Losartan Potassium | 613 | 189 |
| Memantine Hcl | Memantine Hcl | 610 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 514 | 149 |
| Lisinopril | Lisinopril | 493 | 150 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 437 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 117 |
| Montelukast Sodium | Montelukast Sodium | 364 | 113 |
| Fluticasone Propionate | Fluticasone Propionate | 329 | 154 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 321 | 100 |
| Simvastatin | Simvastatin | 321 | 97 |
| Famotidine | Famotidine | 315 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 305 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 298 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 90 |
| Ezetimibe | Ezetimibe | 289 | 84 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 287 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 261 | 98 |
| Azithromycin | Azithromycin | 260 | 187 |
| Trazodone Hcl | Trazodone Hcl | 232 | 76 |
| Glipizide | Glipizide | 212 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 203 | 65 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 202 | 79 |
| Glipizide Er | Glipizide | 193 | 54 |
| Eliquis | Apixaban | 174 | 48 |
| Meloxicam | Meloxicam | 163 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 156 | 80 |
| Baclofen | Baclofen | 153 | 118 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 151 | 46 |
| Furosemide | Furosemide | 144 | 48 |
| Nifedipine Er | Nifedipine | 130 | 37 |
| Alendronate Sodium | Alendronate Sodium | 129 | 38 |
| Meclizine Hcl | Meclizine Hcl | 128 | 53 |
| Ammonium Lactate | Ammonium Lactate | 126 | 55 |
| Clonidine Hcl | Clonidine Hcl | 125 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 125 | 46 |
| Methylprednisolone | Methylprednisolone | 122 | 89 |
| Carvedilol | Carvedilol | 113 | 37 |
| Enalapril Maleate | Enalapril Maleate | 109 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 108 | 39 |
| Donepezil Hcl | Donepezil Hcl | 107 | 31 |
| Ketoconazole | Ketoconazole | 105 | 39 |
| Methocarbamol | Methocarbamol | 101 | 68 |
| Allopurinol | Allopurinol | 96 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 53 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 94 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 28 |
| Farxiga | Dapagliflozin Propanediol | 91 | 27 |
| Atenolol | Atenolol | 90 | 32 |
| Jardiance | Empagliflozin | 90 | 25 |
| Azelastine Hcl | Azelastine Hcl | 88 | 34 |
| Finasteride | Finasteride | 87 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 86 | 37 |
| Mirtazapine | Mirtazapine | 82 | 30 |
| Ozempic | Semaglutide | 72 | 13 |
| Sertraline Hcl | Sertraline Hcl | 71 | 31 |
| Ibuprofen | Ibuprofen | 70 | 61 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | 15 |
| Buspirone Hcl | Buspirone Hcl | 67 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 66 | 17 |
| Xarelto | Rivaroxaban | 65 | 17 |
| Januvia | Sitagliptin Phosphate | 60 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 60 | 17 |
| Latanoprost | Latanoprost | 59 | 19 |
| Pentoxifylline | Pentoxifylline | 58 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 45 |
| Constulose | Lactulose | 56 | 30 |
| Metformin Hcl Er | Metformin Hcl | 55 | 14 |
| Sucralfate | Sucralfate | 54 | 23 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Cilostazol | Cilostazol | 52 | 19 |
| Linzess | Linaclotide | 52 | 12 |
| Valsartan | Valsartan | 51 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 50 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 43 |
| Glimepiride | Glimepiride | 49 | 13 |
| Chlorthalidone | Chlorthalidone | 48 | 18 |
| Amoxicillin | Amoxicillin | 46 | 45 |
| Ciclopirox | Ciclopirox | 46 | 17 |
| Irbesartan | Irbesartan | 46 | 14 |
| Timolol Maleate | Timolol Maleate | 46 | suppressed |
| Mupirocin | Mupirocin | 45 | 35 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 37 |
| Bumetanide | Bumetanide | 43 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 12 |
| Spironolactone | Spironolactone | 42 | 13 |
| Entresto | Sacubitril/Valsartan | 38 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 37 | 18 |
| Lactulose | Lactulose | 37 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 13 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Acyclovir | Acyclovir | 30 | 16 |
| Lumigan | Bimatoprost | 30 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 26 |
| Hydrocortisone | Hydrocortisone | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 15 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 18 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | 11 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Droplet Micron Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Repaglinide | Repaglinide | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | 15 |
| Clonazepam | Clonazepam | 21 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | 13 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 21 | 18 |
| Prednisone | Prednisone | 21 | 11 |
| Temazepam | Temazepam | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 19 | 18 |
| Digoxin | Digoxin | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | 17 |
| Prednisolone Acetate | Prednisolone Acetate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Permethrin | Permethrin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Prolensa | Bromfenac Sodium | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,041.38 · 8 records | Novartis Pharmaceuticals Corporation | GEMTESA, Rhapsido | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error